SPDR S&P Biotech ETF
XBI
XBI
451 hedge funds and large institutions have $6.32B invested in SPDR S&P Biotech ETF in 2019 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 139 increasing their positions, 130 reducing their positions, and 52 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
7% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 130
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
57% less call options, than puts
Call options by funds: $1.14B | Put options by funds: $2.64B
Holders
451
Holding in Top 10
14
Calls
$1.14B
Puts
$2.64B
Top Buyers
| 1 | +$395M | |
| 2 | +$331M | |
| 3 | +$156M | |
| 4 |
Goldman Sachs
New York
|
+$154M |
| 5 |
Barclays
London,
United Kingdom
|
+$145M |
Top Sellers
| 1 | -$111M | |
| 2 | -$54.1M | |
| 3 | -$51.4M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$32M |
| 5 |
JPMPWA
J.P. Morgan Private Wealth Advisors
San Francisco,
California
|
-$31.3M |